Merck & Co., Inc. (LON:0QAH)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 276.13B +75.9% |
| Revenue (ttm) | 50.17B +4.6% |
| Net Income | 2.39B -80.7% |
| EPS | 0.96 -80.4% |
| Shares Out | n/a |
| PE Ratio | 115.46 |
| Forward PE | 17.52 |
| Dividend | 2.56 (2.28%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 30,618 |
| Open | 147.42 |
| Previous Close | 151.27 |
| Day's Range | 147.15 - 154.50 |
| 52-Week Range | 70.15 - 154.50 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?
This article was written by Doug Nathman, with research by his team at Trefis.
Merck price target raised to $160 from $140 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Merck (MRK) to $160 from $140 and keeps a Buy rating on the shares. Merck’s shares surged after positive Phase 3 melanoma…
Merck Stock (MRK) Is a Strong Buy as 3 Top Wall Street Analysts Hike Price Targets
Merck & Co. ($MRK), a U.S. pharmaceutical firm, got a major boost on Thursday, August 20, after investment banks Morgan Stanley ($MS), UBS ($UBS) and Goldman Sachs ($GS) raised their…
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...
Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings
Diane King Hall discusses the sharp sell-off in Advance Auto Parts (AAP) as the guidance shows strong headwinds. Deere (DE) offered plenty of strength in its earnings as construction revenues rise.
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors bought their shares in droves.
Merck price target raised to $170 from $142 at BMO Capital
BMO Capital raised the firm’s price target on Merck (MRK) to $170 from $142 and keeps an Outperform rating on the shares. The company’s success in INTerpath-001 provides positive opportunity…
Moderna Stock (MRNA) Forecast: BofA Upgrades Rating on Cancer Vaccine Update, Goldman Raises Price Target
Moderna ($MRNA) stock rallied 177% on Wednesday after a cancer vaccine from the biotech company and Merck ($MRK) showed positive initial results in its first-ever late-stage trial. Reacting to the fav...
Merck price target raised to $175 from $145 at UBS
UBS raised the firm’s price target on Merck (MRK) to $175 from $145 and keeps a Buy rating on the shares. Moderna (MRNA) and Merck surged 176% and 12%, respectively,…
RBC downgrades Merck on ‘unprecedented valuation’ after vaccine data
RBC Capital analyst Trung Huynh downgraded Merck (MRK) to Sector Perform from Outperform with a price target of $150, up from $142. Merck’s cancer vaccine data exceeded expectations as its…
Merck price target raised to $166 from $141 at BofA
BofA raised the firm’s price target on Merck (MRK) to $166 from $141 and keeps a Buy rating on the shares. Merck’s positive Phase 3 melanoma data strengthen confidence in…
Merck downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Merck (MRK) to Sector Perform from Outperform with a price target of $150, up from $142.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.
Merck upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Merck (MRK) to Overweight from Equal Weight with a price target of $179, up from $116. The recent success for Merck pipeline cancer drugs leads the firm…
Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why
Tempus AI ($TEM) surged nearly 24% on Wednesday after a major Phase 3 cancer vaccine update from Merck ($MRK) and Moderna ($MRNA). The news instantly justified Tempus AI’s recent $1.5…
Leerink says cancer vaccine win should sustain Merck momentum into fall
Leerink notes Merck (MRK) and Moderna (MRNA) announced the top-line recurrence-free survival and distant metastasis-free survival success of the Phase 3 INTerpath-001 study of INT plus pembrolizumab i...
Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update
Pfizer stock was up 3.74% thanks to a clinical trial update from Merck and Moderna that showed the potential of an MRNA vaccine as a cancer treatment.
Merck, Moderna Stocks Soar After Melanoma Trial Success
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that th...
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results
Moderna's personalized mRNA cancer therapy, developed with Merck , reduced the risk of melanoma recurrence and spread when used in combination with the U.S. drugmaker's blockbuster treatment Keytruda...
Merck, Moderna Melanoma Vaccine Study Succeeds
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin...
U.S. Treasury Boosts Debt Buybacks, UAE Cuts Off Iran, MRNA & MRK Melanoma Trial Results
The U.S. Treasury is "at least" doubling debt buybacks for longer-dated nominal coupon securities, causing a surge in fixed income activity after yields hit highs not seen in years. Kevin Hincks expla...
'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial
Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial r...
Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market
Stock markets are waited on minutes of the Fed's most recent monetary policy meeting for any clues about the forward path on interest rates.
Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
Merck and Moderna said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced melanoma skin cancer recurrence and spread compared with Keytruda alo...
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial. The combination regimen met the main study goal of significantly ...